Charlottes Web Holdings Inc (CWBHF)
0.2198
+0.01
(+4.22%)
USD |
OTCM |
Apr 19, 15:55
Charlottes Web Holdings SG&A Expense (Quarterly): 18.60M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 18.60M |
September 30, 2023 | 19.89M |
June 30, 2023 | 19.63M |
March 31, 2023 | 17.51M |
December 31, 2022 | 21.41M |
September 30, 2022 | 11.03M |
June 30, 2022 | 17.26M |
March 31, 2022 | 20.36M |
December 31, 2021 | 24.38M |
September 30, 2021 | 24.30M |
June 30, 2021 | 25.18M |
March 31, 2021 | 23.79M |
December 31, 2020 | 54.03M |
September 30, 2020 | 15.74M |
Date | Value |
---|---|
June 30, 2020 | 17.67M |
March 31, 2020 | 17.23M |
December 31, 2019 | 27.05M |
September 30, 2019 | 13.77M |
June 30, 2019 | 12.61M |
March 31, 2019 | 12.62M |
December 31, 2018 | 12.41M |
September 30, 2018 | 9.533M |
June 30, 2018 | 8.01M |
March 31, 2018 | 6.173M |
December 31, 2017 | 5.053M |
September 30, 2017 | 4.721M |
June 30, 2017 | 3.69M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
11.03M
Minimum
Sep 2022
54.03M
Maximum
Dec 2020
21.13M
Average
19.63M
Median
Jun 2023
SG&A Expense (Quarterly) Benchmarks
NovaBay Pharmaceuticals Inc | 2.609M |
Palatin Technologies Inc | 3.033M |
iBio Inc | 2.961M |
Theriva Biologics Inc | 2.021M |
Ampio Pharmaceuticals Inc | 0.973M |